Manufacturing Deviation Case Studies – Page 4

Unapproved process parameter change during inspection preparation – CAPA ineffectiveness identified

The first signs of a problem often manifest as anomalies in product quality metrics, unexpected deviations in batch records, or emerging trends in laboratory results. In this case, during routine…

Unapproved process parameter change during commercial campaign – FDA inspection observation breakdown

During routine production of a critical biopharmaceutical product, several symptoms emerged which indicated a potential deviation from established practices. Operators noted inconsistencies in batch quality, evidenced by out-of-specification (OOS) results…

Unapproved process parameter change during commercial campaign – FDA inspection observation breakdown

Analysis of an Unapproved Change in Process Parameters During a Commercial Campaign In the landscape of pharmaceutical manufacturing, maintaining compliance with Good Manufacturing Practices (GMP) is crucial to ensure product…

Batch executed with expired SOP during commercial campaign – root cause analysis failure explained

Upon execution, the manufacturing team observed several warning signals that indicated the use of an expired SOP:Click to read the full article.

Batch executed with expired SOP during commercial campaign – root cause analysis failure explained

In this scenario, the initial indicators of a potential issue arose from both the production floor and quality control lab. The following symptoms were observed:Click to read the full article.

Deviation closed without effectiveness check during changeover – FDA inspection observation breakdown

During routine operational monitoring on the production floor, the quality assurance team noted several irregularities that triggered an investigation. The signals included:Click to read the full article.

Deviation closed without effectiveness check during changeover – FDA inspection observation breakdown

In early February, during routine production operations in a tablet manufacturing facility, quality control (QC) personnel noted an unusual trend in the potency assay results of product batches processed after…

Process change implemented without QA approval during routine manufacturing – regulatory impact assessment case study

Case Study: Impact of Unapproved Process Change during Routine Manufacturing In a recent incident at a pharmaceutical manufacturing facility, a process change was implemented without the necessary Quality Assurance (QA)…

Process change implemented without QA approval during routine manufacturing – regulatory impact assessment case study

During routine quality control checks, operators noticed discrepancies in product consistency, leading to out-of-specification (OOS) results. Specifically, the following signals were detected:Click to read the full article.

Equipment used without release during routine manufacturing – FDA inspection observation breakdown

The initial detection of the issue arose when a batch review identified non-conformance associated with a specific piece of equipment used in the final stages of the manufacturing process. Symptoms…

Equipment used without release during routine manufacturing – FDA inspection observation breakdown

The operational team identified deviations when a routine batch was prepared for release testing. Symptoms included:Click to read the full article.

Unplanned hold time extension during inspection preparation – regulatory impact assessment case study

Upon receiving notice of an impending regulatory inspection, the Quality Control (QC) lab noted inconsistencies in the sample preparation process. Specifically, multiple batches prepared for sample analysis exhibited an extended…